New malaria vaccine may be too costly for success
A promising new malaria vaccine being tested by GlaxoSmithKline is a step in the right direction, but much more economical methods are needed.
Laura Harrington, professor of entomology at Cornell University and an expert in global health and epidemiology, said that despite a resurgence in the global effort to fight malaria, the war on this deadly mosquito borne infection has overwhelmed scientists, policy makers, and government officials alike.
She said that major challenges, like behavioral and biochemical resistance by malaria vectors, and the flood of fake antimalarial drugs in the marketplace have all taken their toll.
Harrington asserted that the world’s first successful malaria vaccine is almost within reach. A malaria vaccine has long been viewed as the ‘holy grail of tropical medicine.’
Although the GlaxoSmithKline RTS vaccine doesn’t protect all immunized children – only a 46 percent reduction in malaria incidence for children 5 to 17 months, and 27 percent for those 6 to 12 weeks of age – it is better than no vaccine, and it could be used together with other strategies like vector control to reduce malaria illness and mortality.
Source: ANI
Category: Features, Pharmaceuticals
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
